Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion

被引:0
|
作者
Tomohiro Kawaguchi
Yukihiko Sonoda
Ichiyo Shibahara
Ryuta Saito
Masayuki Kanamori
Toshihiro Kumabe
Teiji Tominaga
机构
[1] Tohoku University Graduate School of Medicine,Department of Neurosurgery
[2] Yamagata University School of Medicine,Department of Neurosurgery, Faculty of Medicine
[3] Kitasato University School of Medicine,Department of Neurosurgery
来源
Journal of Neuro-Oncology | 2016年 / 129卷
关键词
Glioma; WHO grade III; IDH; 1p/19q; Surgery; Magnetic resonance imaging;
D O I
暂无
中图分类号
学科分类号
摘要
The prognosis of patients with WHO grade III gliomas is highly dependent on their genomic status such as the isocitrate dehydrogenase (IDH) 1/2 mutation and1p/19q co-deletion. However, difficulties have been associated with determining which tumors have certain genomic profiles by preoperative radiographical modalities, and the role of surgical resection in achieving better outcomes remains unclear. This retrospective study included 124 consecutive patients with newly diagnosed grade III gliomas. The genomic status of IDH1/2 and 1p/19q was analyzed in these patients. Tumors were then divided into 3 subgroups based on their genomic status; the IDH 1/2 mutation with the 1p/19q co-deletion (1p/19q co-del), the IDH 1/2 mutation without the 1p/19q co-deletion (non-1p/19q co-del), and the IDH 1/2 wild type (IDH wt). Survival times were compared between patients who underwent gross total resection and those who did not (GTR versus non-GTR). The relationships between genomic statuses and MR imaging characteristics such as ring-like or nodular enhancements by gadolinium, and very low intensity on T1-weighted images with blurry enhancements (T1VL) were also examined. Among all patients with grade III gliomas, GTR patients had longer median survival and progression-free times than those of non-GTR patients (undefined versus 87 months, p = 0.097, and 124 versus 34 months, p = 0.059, respectively). No significant differences were observed in survival between GTR and non-GTR patients in the 1p/19q co-del group (p = 0.14), or between GTR and non-GTR patients in the IDH wt group (26 and 27 months, p = 0.29). On the other hand, in non-1p/19q co-del group, survival was significantly longer in GTR patients than in non-GTR patients (undefined versus 77 months, p = 0.005). Radiographically, T1VL was detected in most tumors in the non-1p/19q co-del group (78.2 %), but only 6 (21.4 %) and 17 (41.5 %) tumors in the 1p/19q co-del and IDH wt groups, respectively. A correlation was not found between other genomic subgroups and MR imaging findings. Strict surgical removal is important to improve the prognosis of patients with grade III gliomas, especially for tumors with the IDH 1/2 mutation without the 1p/19q co-deletion. The MR finding of T1VL can be used to select candidates for more radical resection.
引用
收藏
页码:505 / 514
页数:9
相关论文
共 50 条
  • [1] Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion
    Kawaguchi, Tomohiro
    Sonoda, Yukihiko
    Shibahara, Ichiyo
    Saito, Ryuta
    Kanamori, Masayuki
    Kumabe, Toshihiro
    Tominaga, Teiji
    JOURNAL OF NEURO-ONCOLOGY, 2016, 129 (03) : 505 - 514
  • [2] Co-Deletion of Chromosome 1p/19q and IDH1/2 Mutation in Glioma Subsets of Brain Tumors in Chinese Patients
    Ren, Xiaohui
    Cui, Xiangli
    Lin, Song
    Wang, Junmei
    Jiang, Zhongli
    Sui, Dali
    Li, Jing
    Wang, Zhongcheng
    PLOS ONE, 2012, 7 (03):
  • [3] Atypical Central Neurocytoma Harboring the 1p/19q Co-deletion
    Allen-Proctor, Kathy
    Fullmer, Joseph
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2015, 74 (06): : 637 - 638
  • [4] Anaplastic Oligodendroglioma with IDH Mutation and 1p/19q Co-Deletion in a Patient with Ollier Disease
    Sadasivuni, Rajesh
    Rauschkolb, Paula
    NEUROLOGY, 2016, 86
  • [5] Anaplastic Oligodendroglioma with IDH Mutation and 1p/19q Co-Deletion in a Patient with Oilier Disease
    Sadasivuni, Rajesh
    Rauschkolb, Paula
    NEUROLOGY, 2016, 86
  • [6] GPGPS: a robust prognostic gene pair signature of glioma ensembling IDH mutation and 1p/19q co-deletion
    Cheng, Lixin
    Wu, Haonan
    Zheng, Xubin
    Zhang, Ning
    Zhao, Pengfei
    Wang, Ran
    Wu, Qiong
    Liu, Tao
    Yang, Xiaojun
    Geng, Qingshan
    BIOINFORMATICS, 2023, 39 (01)
  • [7] Connectomic insights into the impact of 1p/19q co-deletion in dominant hemisphere insular glioma patients
    Yang, Zuo-cheng
    Xue, Bo-wen
    Song, Xin-yu
    Yin, Chuan-dong
    Yeh, Fang-cheng
    Li, Gen
    Deng, Zheng-hai
    Sun, Sheng-jun
    Hou, Zong-gang
    Xie, Jian
    FRONTIERS IN NEUROSCIENCE, 2024, 18
  • [8] 18F-DOPA uptake does not correlate with IDH mutation status and 1p/19q co-deletion in glioma
    Francesco Cicone
    Luciano Carideo
    Claudia Scaringi
    Antonietta Arcella
    Felice Giangaspero
    Francesco Scopinaro
    Giuseppe Minniti
    Annals of Nuclear Medicine, 2019, 33 : 295 - 302
  • [9] 18F-DOPA uptake does not correlate with IDH mutation status and 1p/19q co-deletion in glioma
    Cicone, Francesco
    Carideo, Luciano
    Scaringi, Claudia
    Arcella, Antonietta
    Giangaspero, Felice
    Scopinaro, Francesco
    Minniti, Giuseppe
    ANNALS OF NUCLEAR MEDICINE, 2019, 33 (04) : 295 - 302
  • [10] Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial
    van den Bent, Martin J.
    Klein, Martin
    Smits, Marion
    Reijneveld, Jaap C.
    French, Pim J.
    Clement, Paul
    de Vos, Filip Y. F.
    Wick, Antje
    Mulholland, Paul J.
    Taphoorn, Martin J. B.
    Lewis, Joanne
    Weller, Michael
    Chinot, Olivier L.
    Kros, Johan M.
    de Heer, Iris
    Verschuere, Tina
    Coens, Corneel
    Golfinopoulos, Vassilis
    Gorlia, Thierry
    Idbaih, Ahmed
    LANCET ONCOLOGY, 2018, 19 (09): : 1170 - 1179